FGF21 Secretion Enhancement System via Synergistic Combinations

A novel system integrating a Bifidobacterium bacterium with distinct technologies such as AI, IoT, blockchain, and new materials to enhance FGF21 secretion, offering improved efficacy and personalized health management.

The original patent disclosed a composition for promoting FGF21 secretion, but it had limitations in terms of efficacy and customization. The new inventive concept addresses these limitations by combining the Bifidobacterium bacterium with advanced technologies to create a more powerful and personalized system.

The system comprises a Bifidobacterium bacterium, which promotes FGF21 secretion, integrated with various technologies. For instance, an AI-powered personalized nutrition planning module provides customized dietary plans based on the subject's genetic profile, enhancing the bacterium's efficacy. A blockchain-based health data management system tracks and analyzes the subject's health data to optimize the bacterium's administration and dosage. A novel, edible, graphene-based material enhances the bacterium's bioavailability and promotes its colonization in the gut. A wearable IoT device tracks the subject's physiological parameters, and the bacterium promotes FGF21 secretion in response to the tracked parameters. Machine learning algorithms analyze the subject's genetic profile, health data, and lifestyle factors to provide a personalized prediction of the bacterium's efficacy.

The new inventive concept introduces a synergistic combination of distinct technologies with the Bifidobacterium bacterium, creating a novel system that enhances FGF21 secretion and provides personalized health management. The integration of these technologies with the bacterium is non-obvious and represents a significant advancement over the original patent.

Alternative embodiments of the system could include integrating the Bifidobacterium bacterium with other AI-powered modules, such as personalized exercise planning or stress management. Variations could also include using different types of bacteria or combining the system with other health monitoring devices.

The FGF21 secretion enhancement system has significant commercial potential in the health and wellness industry, particularly in the areas of personalized nutrition, health monitoring, and disease prevention. Target markets could include health-conscious consumers, athletes, and individuals with chronic diseases.